NRX Pharmaceuticals Warrant
NRXPW
NRXPW was delisted on the 22nd of May, 2026.
3 hedge funds and large institutions have $3.69K invested in NRX Pharmaceuticals Warrant in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
50% more funds holding
Funds holding: 2 → 3 (+1)
0.01% more ownership
Funds ownership: 0.03% → 0.03% (+0.01%)
14% less capital invested
Capital invested by funds: $4.28K → $3.69K (-$597)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$1.07K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
YCM
1
Yakira Capital Management
Westport,
Connecticut
| $3.08K | – | – | – |
|
|
2
UBS Group
Zurich,
Switzerland
| $604 | +$1.07K | +3,356 | New |
|
NRXPW Hedge Fund Activity: Q1 2023 in Review
3 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals Warrant (NRXPW) for Q1 2023, worth a combined $3.69K — down 14% from $4.28K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new NRXPW positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $1.07K.
- 3 institutional investors held NRX Pharmaceuticals Warrant (NRXPW) as of Q1 2023, up from 2 in Q4 2022.
- Funds reported $3.69K of NRX Pharmaceuticals Warrant stock for Q1 2023, down 14% quarter-over-quarter.
- 1 fund opened new NRX Pharmaceuticals Warrant positions in Q1 2023 and 0 closed out, a net change of +1 holder.
- The largest NRX Pharmaceuticals Warrant buyer in Q1 2023 was UBS Group, an estimated $1.07K added.
Based on aggregated 13F filings for Q1 2023.